Loading…
Loading…
there was some commentary in the deck around seeing a healthy increase in proposals in the first quarter
AI investments in drug discovery are going to lead to more preclinical testing longer term. Are you seeing that play out at all yet
licensing from China, what impact that would have relative to maybe some of the licensing deals that have been more U.S.-centric
Does further progress there eliminate the remaining uncertainty? Or are there any other factors out there
whether or not it's fair to think about headcount growth in DSA as a reasonable proxy for that segment growth in 2026
how that exactly drove the outperformance in the second quarter. Is it just that, that work burned faster than expected?
Just wondering if you can provide some more detail around how each of those offerings are being used currently and why they aren't being used more frequently already in preclinical?
I'm wondering if you have any thoughts on whether some of the mixed messaging from the FDA will prevent drug developers from really leaning into the guidance about reducing animal testing?
Was a little bit surprised by the impairment for the biologics test business. I think over the last couple of quarters, you've talked about seeing a continued rebound